Evidence map›Paper›PMID 39928264›Full record

ArticleBreast cancer research and treatment2025

The impact of cardiovascular risk factors on cancer progression: a prospective study in female breast cancer survivors.

Xinyi Feng, Zhengyi Deng, Michelle S McCullough, Betty J May, Erica Selznick, Jennifer Y Sheng, Avonne E Connor, Deborah K Armstrong, Kala Visvanathan

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Xinyi FengDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe Street, Room E6142, Baltimore, MD, 21205, USA.
Zhengyi DengStanford School of Medicine, Stanford, CA, USA.
Michelle S McCulloughDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe Street, Room E6142, Baltimore, MD, 21205, USA.
Betty J MayDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe Street, Room E6142, Baltimore, MD, 21205, USA.
Erica SelznickDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe Street, Room E6142, Baltimore, MD, 21205, USA.
Jennifer Y ShengThe Johns Hopkins School of Medicine, Baltimore, MD, USA.
Avonne E ConnorDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe Street, Room E6142, Baltimore, MD, 21205, USA.
Deborah K ArmstrongThe Johns Hopkins School of Medicine, Baltimore, MD, USA.
Kala VisvanathanDepartment of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, 615 N. Wolfe Street, Room E6142, Baltimore, MD, 21205, USA. kvisvan1@jhu.edu.

Funding

Breast Cancer Research Foundation P30CA06973NIH HHS T32-CA009314
6 · The paper itself

Abstract

purposeTo examine the effect of selected cardiovascular disease (CVD) risk factors over time on early cancer outcomes in breast cancer (BC) survivors.

methodsA prospective study was conducted among women aged 20-65 years with an incident invasive BC enrolled in the Breast and Ovarian Surveillance Service (BOSS) Cohort between 2005 and 2013. CVD risk based on selected risk factors was assessed at baseline and two follow-ups. Participants were categorized into low, medium, and high-risk groups. The primary outcome was BC recurrence (distant or local) or second primary cancer (SPC). Kaplan-Meier failure curves and multivariable Cox proportional hazard models were performed to compare the hazards across CVD risk score groups.

resultsA total of 212 women with invasive BC contributed to 2211 person-years (median follow-up 11.7 years), 103 had low, 73 medium, and 36 high CVD risk scores at baseline. In multivariable analyses, BC survivors with medium CVD risk score had 2.09 times higher risk (95%CI = 1.09-4.02; p = 0.027) of recurrence/SPC compared to survivors with low CVD risk score. This association was particularly pronounced in postmenopausal women, those with estrogen receptor-positive BC, regional disease, or newly diagnosed BC. After excluding women taking cardiac medications, a higher risk of recurrence/SPC was also observed among those in the high-CVD-risk-score group, although not significant.

conclusionHigher CVD risk score based on selected risk factors was significantly associated with BC recurrence or SPC, particularly in certain subgroups. Monitoring and treating a combination of CVD risk factors in BC survivors may help reduce BC progression.

Indexed as

Breast NeoplasmsCancer SurvivorsCardiovascular DiseasesAdultAgedDisease ProgressionFemaleFollow-Up StudiesHeart Disease Risk FactorsHumansMiddle AgedNeoplasm Recurrence, LocalNeoplasms, Second PrimaryProspective StudiesRisk FactorsYoung AdultBreast cancerCardiovascular diseaseCVDRecurrenceSecond primary cancer

Identifiers

PMID39928264

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.